Study tests if patients grasp their own Alzheimer's biomarker news

NCT ID NCT04818255

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with mild cognitive impairment or Alzheimer's-type dementia can understand and decide about receiving their PET scan results for amyloid and tau proteins. Researchers educated 152 participants and their care partners, then assessed their ability to make an informed choice. The goal was to learn how to best share this sensitive biomarker information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors and families better understand how to share Alzheimer's risk information in a way that patients can understand and use.

What could go wrong

This is a small, completed study focused on education and decision-making, not treatment. Results may not apply to all patients or settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Medical School, Department of Psychiatry

    Ann Arbor, Michigan, 48105, United States